Based in London, Ternary Therapeutics was founded by experienced drug hunters who helped pioneer targeted protein degradation and the application of AI in drug discovery. Ternary’s platform integrates advanced AI models with molecular dynamics simulations to rationally design molecular glues that do not require a pre-existing druggable site on either protein, overcoming a major limitation of conventional approaches.